Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

DOI: 10.1148/radiol.2493080240
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Krug, B.
Right arrow Articles by Vander Borght, T.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krug, B.
Right arrow Articles by Vander Borght, T.
(Radiology 2008;249:836-844.)
© RSNA, 2008

Evidence-based Practice

Role of PET in the Initial Staging of Cutaneous Malignant Melanoma: Systematic Review1

Bruno Krug, MD, Ralph Crott, MPH, PhD, Max Lonneux, MD, PhD, Jean-François Baurain, MD, PhD, Anne-Sophie Pirson, MD, and Thierry Vander Borght, MD, PhD

1 From the Nuclear Medicine Division, Mont-Godinne University Hospital, Université Catholique de Louvain, 1 Dr Therasse, B-5530 Yvoir, Belgium (B.K., A.P., T.V.B.); and Department of Public Health (R.C.), Nuclear Medicine Division (M.L.), and Department of Oncology (J.B.), Saint-Luc University Hospital, Université Catholique de Louvain, Brussels, Belgium. Received February 5, 2008; revision requested March 25; revision received May 3; accepted June 6; final version accepted June 23. Address correspondence to B.K.

Purpose: To calculate summary estimates of the diagnostic performance of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging in the initial staging of cutaneous malignant melanoma (CMM), following the new American Joint Committee on Cancer (AJCC) staging classification on per-patient and per-lesion bases.

Materials and Methods: MEDLINE, EMBASE, Web of Science, and Cochrane Database of Systematic Reviews databases, and reference lists of reviews and included papers were searched, without any language restrictions, for relevant articles published before March 2007. Two reviewers independently assessed study eligibility and methodologic quality by using the quality assessment of diagnostic accuracy studies checklist. A pooled random effect was estimated and a fixed coefficient regression model was used to explore the existing heterogeneity.

Results: Twenty-eight studies involving 2905 patients met the inclusion criteria. The pooled estimates of FDG PET for the detection of metastasis in the initial staging of CMM were sensitivity, 83% (95% confidence interval [CI]: 81%, 84%); specificity, 85% (95% CI: 83%, 87%); positive likelihood ratio (LR), 4.56 (95% CI: 3.12, 6.64); negative LR, 0.27 (95% CI: 0.18, 0.40); and diagnostic odds ratio, 19.8 (95% CI: 10.8, 36.4). Results from eight studies suggested that FDG PET was associated with 33% disease management changes (range, 15%–64%).

Conclusion: There is good preliminary evidence that FDG PET is useful for the initial staging of patients with CMM, especially as adjunctive role in AJCC stages III and IV, to help detect deep soft-tissue, lymph node, and visceral metastases. FDG PET–computed tomographic imaging seemed to be more precise than PET alone, as suggested by four eligible studies. Further evaluation by using a well-designed prospective study, with clinical outcome–focused measures and cost effectiveness analysis, is needed to clarify the appropriate role of FDG PET in CMM staging.

Supplemental material: http://radiology.rsnajnls.org/cgi/content/full/249/3/836/DC1

© RSNA, 2008






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2008 by the Radiological Society of North America.